Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas (A051701)
Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas (A051701)
Trial Category:
Lymphoma
Phase
II
Contact(s)
Location(s)
Methodist Estabrook Cancer Center, Omaha, NE
